Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Galena Biopharma Inc (GALE) A Good Stock To Buy?

Hedge fund managers like David Einhorn, Dan Loeb, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing their quarterly 13F filings. One of the most fertile grounds for large abnormal returns is hedge funds’ most popular small-cap picks, which are not so widely followed and often trade at a discount to their intrinsic value. In this article we will check out hedge fund activity in another small-cap stock: Galena Biopharma Inc (NASDAQ:GALE).

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research


Galena Biopharma Inc was in 4 hedge funds’ portfolio at the end of September. GALE shareholders have witnessed a decrease in hedge fund sentiment of late. There were 5 hedge funds in our database with GALE positions at the end of the previous quarter. At the end of this article we will also compare GALE to other stocks including Career Education Corp. (NASDAQ:CECO), Global Ship Lease, Inc. (NYSE:GSL), and Agilysys, Inc. (NASDAQ:AGYS) to get a better sense of its popularity.

Follow Galena Biopharma Inc. (NASDAQ:GALE)
Trade (NASDAQ:GALE) Now!

How are hedge funds trading Galena Biopharma Inc (NASDAQ:GALE)?

Heading into Q4, a total of 4 of the hedge funds tracked by Insider Monkey were long in this stock, a change of -20% from the second quarter. With the smart money’s capital changing hands, there exists an “upper tier” of notable hedge fund managers who were boosting their stakes significantly.

Of the funds tracked by Insider Monkey, Anand Parekh’s Alyeska Investment Group had the biggest call position in Galena Biopharma Inc (NASDAQ:GALE), worth close to $2.5 million, amounting to less than 0.1%% of its total 13F portfolio. The second largest stake is held by Ken Griffin of Citadel Investment Group, with a $0.1 million position; the fund has less than 0.1%% of its 13F portfolio invested in the stock. Other hedge funds that hold long positions contain quant fund D. E. Shaw and Ken Fisher’s Fisher Asset Management.

Seeing as Galena Biopharma Inc (NASDAQ:GALE) has experienced a declination in interest from the entirety of the hedge funds we track, it’s safe to say that there were a few fund managers that slashed their positions entirely at the end of the third quarter. Intriguingly, James Dondero’s Highland Capital Management sold off the biggest stake of the 700 funds tracked by Insider Monkey, totaling an estimated $2.4 million in stock, and Paul Tudor Jones of Tudor Investment Corp was right behind this move, as the fund cut its tiny $19 thousand position.

Let’s also take a look at hedge fund activity in other stocks similar to Galena Biopharma Inc (NASDAQ:GALE). We will take a look at Career Education Corp. (NASDAQ:CECO), Global Ship Lease, Inc. (NYSE:GSL), Agilysys, Inc. (NASDAQ:AGYS), and BankFinancial Corporation (NASDAQ:BFIN). All of these stocks’ market caps are closest to GALE’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
CECO 13 48003 -3
GSL 5 6417 1
AGYS 13 141888 3
BFIN 4 34741 1

As you can see these stocks had an average of 8.75 hedge funds with bullish positions and the average amount invested in these stocks was $58 million. Career Education Corp. (NASDAQ:CECO) is the most popular stock in this table. On the other hand BankFinancial Corporation (NASDAQ:BFIN) is the least popular one with only 4 bullish hedge fund positions. Compared to these stocks Galena Biopharma Inc (NASDAQ:GALE) is at the bottom of the range. Considering that hedge funds aren’t fond of this stock, it may be a good idea to analyze it in detail and understand why the smart money isn’t behind this stock. This isn’t necessarily bad news. Although it is possible that hedge funds may think the stock is overpriced and view the stock as a short candidate, they may not be very familiar with the bullish thesis. In either case more research is warranted.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!